Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals' stock has experienced volatility over the past six months. The share price saw a significant increase of 365.50% from May 5, 2025, to May 1, 2026, but decreased by 26.7% from January 1, 2026, to May 9, 2026. Recent financial results have played a role, with the company reporting its Q1 2026 earnings on April 30, 2026. Phathom Pharmaceuticals more than doubled its revenue from Q1 2025 to Q1 2026, and its Q1 2026 revenue of $58.3 million exceeded analyst estimates. The company also narrowed its Q1 net loss to US$30.37 million from US$94.32 million a year earlier. Phathom reaffirmed its full-year 2026 net revenue guidance of $320 million to $345 million and anticipates achieving operating profitability, excluding stock-based compensation, starting in the third quarter of 2026. An FDA correction to the Orange Book listing confirmed 10 years of regulatory exclusivity for VOQUEZNA tablets through May 3, 2032.

Phathom Pharmaceuticals' products and services experience demand seasonality. The company stated that its Q1 2026 revenue was somewhat light compared to internal expectations due to market access seasonality and other factors. Q1 total prescription numbers showed expected seasonality, indicating that demand for Phathom Pharmaceuticals' products, particularly VOQUEZNA, can fluctuate with seasonal patterns.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States. Its primary product is VOQUEZNA (vonoprazan), a potassium-competitive acid blocker (P-CAB) that has completed Phase III clinical trials for various conditions.

Phathom Pharmaceuticals, Inc. is headquartered in Florham Park, New Jersey, with its R&D headquarters in Buffalo Grove, Illinois. The company focuses on the United States for development and commercialization, but vonoprazan is approved in Japan and other countries across Asia and Latin America.

Phathom Pharmaceuticals has maintained a positive brand reputation over the past year, driven by the commercial success and growth potential of VOQUEZNA. The company has a consensus "Strong Buy" rating from analysts. VOQUEZNA has demonstrated significant commercial growth, with a 28% increase in prescriptions filled over Q2 2025 and over 1.1 million total prescriptions filled to date, reaching approximately 230,000 patients. The FDA's correction to the Orange Book listing, confirming 10 years of regulatory exclusivity for VOQUEZNA tablets through May 3, 2032, was a significant positive event. Concerns raised by "bears" include the company's dependence on a single product, potential failures in product development and commercialization, and financial stability due to reported net losses.

Phathom Pharmaceuticals, Inc. has significant institutional ownership, with 173 institutional owners and shareholders holding 77.47% of the company. Major institutional owners include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Invesco Ltd., BlackRock, Inc., Carlyle Group Inc., Vanguard Group Inc, Ensign Peak Advisors, Inc, Millennium Management Llc, NEA Management Company, LLC, and 683 Capital Management, LLC. Insiders hold 9.33% of the company's stock. Medicxi Ventures Management Jersey Ltd is identified as the largest individual shareholder, owning 9.36% of the company.